<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the hypothesis that gemtuzumab ozogamicin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial </plain></SENT>
<SENT sid="1" pm="."><plain>Toxicity was defined as grades III-IV organ damage, engraftment failure or <z:hpo ids='HP_0011420'>death</z:hpo> within 30 days. 'Response' was engraftment and remission (CR) on day +30 </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to determine the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> dose (2, 4 or 6 mg m(-2)) giving the best trade-off between toxicity and response </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were not candidates for myeloablative regimens </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment plan: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> (day -12), fludarabine 30 mg m(-2) (days -5 to -2), melphalan 140 mg m(-2) (day -2) and HSCT (day 0) </plain></SENT>
<SENT sid="5" pm="."><plain>GVHD prophylaxis was tacrolimus and mini-<z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Diagnoses were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n=47), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n=4) or <z:mp ids='MP_0005481'>CML</z:mp> (n=1) </plain></SENT>
<SENT sid="7" pm="."><plain>Median age was 53 years (range, 13-72) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but three patients were not in CR </plain></SENT>
<SENT sid="9" pm="."><plain>Donors were related (n=33) or unrelated (n=19) </plain></SENT>
<SENT sid="10" pm="."><plain>Toxicity and response rates at 4 mg m(-2) were 50% (n=4) and 50% (n=4) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> dose was de-escalated to 2 mg m(-2): 18% had toxicity (n=8) and 82% responded (n=36) </plain></SENT>
<SENT sid="12" pm="."><plain>100-day TRM was 15%; one patient had reversible hepatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Median follow-up was 37 months </plain></SENT>
<SENT sid="14" pm="."><plain>Median event-free and overall survival was 6 and 11 months </plain></SENT>
<SENT sid="15" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> 2 mg m(-2) can be safely added to fludarabine/melphalan, and this regimen merits further evaluation </plain></SENT>
</text></document>